Drug intelligence / Profile preview

IGNX001

Development stage: Phase 1
Lead developer: IgGenix
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

IGNX001 is an investigational, subcutaneously administered **fixed combination of two high-affinity human peanut-specific IgG4 monoclonal antibodies** developed by IgGenix for peanut allergy. The antibodies bind immunodominant epitopes on peanut allergens, including Ara h 2 and Ara h 6, competitively blocking allergen engagement with pathogenic IgE and thereby preventing downstream mast-cell and basophil activation that can cause allergic reactions and anaphylaxis after accidental peanut exposure. It is being evaluated in the randomized, placebo-controlled Phase 1 ACCELERATE Peanut study.

Targets

Ara h 2

Beyond the preview

Go deeper on IGNX001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGNX001.

Explore the full profile